Jay Liu, Ph.D., is a biotech veteran and an entrepreneur with more than 20 years of experience in the pharmaceutical industry. He received his Ph.D. in pharmacology from the School of Pharmacy, State University of New York at Buffalo. Following a brief postdoctoral training at the National Institutes of Health, he worked at several U.S. pharmaceutical companies including Pharmacopeia, Merck and AstraZeneca. As a project leader and team leader, he delivered five investigational new drugs (INDs), with two of them having completed Phase II clinical studies. In addition to his contributions to drug discovery, he has published more than 30 research papers and has 10 patent applications.
In 2010, Liu returned to China and co-founded Rugen Therapeutics Inc. with financial support from Fidelity Investment. As the chief security officer and general manager, he built Rugen’s internal central nervous system (CNS) drug discovery capacity and external alliances with academic labs and contract research organizations worldwide. Within five years, he delivered several innovative CNS therapeutic candidate drugs that were out-licensed to Allergan for treatment of autism and bipolar disorders. Before joining Southern Research in August 2017, Liu was CEO of Nanjing Galaxy Biotech Ltd. and Suzhou Galaxy Biopharma Ltd., leading a team of nearly 70 scientists to discover and develop innovative biologics for the treatment of cancer and autoimmune disorders.